Catalent to tap particle size engineering industry with Micron buy
Last week CDMO Catalent acquired Micron Technologies, a provider of particle size engineering technologies, with the aim of improving its early stage tech offering.
Last week CDMO Catalent acquired Micron Technologies, a provider of particle size engineering technologies, with the aim of improving its early stage tech offering.
Investors only back drug innovators because they have to according to Index Venture Management's Kevin Johnson, who says less risky 'first to be second' firms are actually much more attractive.
With biologics declared as its main driver over the next few years, CDMO Wuxi is seeing rapid manufacturing growth and planning two new facilities in the next two years.
GSK Australia will invest about $27m (€22m) in manufacturing technology to expand its Boronia site in the suburbs of Melbourne, Australia.
Ongoing concerns about marketing practices have taken the shine of a report suggesting Big Pharma efforts have improved parients' access to drugs in developing countries over the past two years.
After fending off hostile takeover bids from Valeant for nearly seven months, Allergan is finally agreeing to a takeover, but with Ireland-based Actavis.
Recipharm has bought Portugal-based contractor Lusomedicamenta for SEK1bn ($1349m) following up on the plan to add manufacturing capacity that it outlined after going public this summer.